Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

EGM Statement

30 Jun 2008 12:12

RNS Number : 8010X
Vernalis PLC
30 June 2008
 



30 June 2008

VERNALIS PLC

RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 30 JUNE 2008

Vernalis plc announces that all resolutions proposed to shareholders at the Extraordinary General Meeting held earlier today were duly passed.

All resolutions were approved on a show of hands. The number of proxy votes received for each resolution is set out below.

Resolution

For (including discretionary votes)*

Against*

Withheld

Ordinary Resolution

1. To approve the sale by the Company of Apokyn® and the US Commercial Operations

143,094,025

(99.98%)

25,322

(0.02%)

7,576

2. To increase the Company's authorised share capital and to authorise the Directors to allot relevant securities 

143,060,249

(99.98%)

28,285

(0.02%)

38,389

Special Resolution

3. To authorise the Directors to allot equity securities for cash without application of statutory pre-emption rights

142,665,007

(99.72%)

403,407

(0.28%)

58,509

*NB: Percentage of votes cast excludes withheld votes

Vernalis has forwarded to the Document Viewing Facility of the Financial Services Authority two copies of the resolutions passed at the Extraordinary General Meeting. These copies will shortly be available for viewing at the Document Facility, at the address below, from 9.00am to 5.30pm on every weekday except bank holidays.

Document Viewing Facility

The Financial Services Authority

25 The North ColonadeCanary Wharf

London E14 5HS

Tel: 020 7066 1000

Printed copies of the resolutions may be obtained by writing to The Company Secretary, Vernalis plc, Oakdene Court, 613 reading Road, Winnersh, Berkshire RG41 5UA.

Enquiries:

Vernalis plc +44 (0)118 977 3133

Tony Weir, Chief Financial Officer

Brunswick Group +44 (0)20 7404 5959

Jon Coles

Justine McIlroy

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EGMBDLLLVQBLBBQ
Date   Source Headline
18th Mar 20161:06 pmRNSHolding(s) in Company
17th Mar 20167:00 amRNSUnaudited interim results for 6 months to 31/12/15
4th Feb 20163:34 pmRNSNotice of Results for Six Months Ended 31/12/2015
19th Jan 20162:36 pmRNSHolding(s) in Company
6th Jan 20167:00 amRNSVernalis Announces Adenosine Antagonist Licensee
31st Dec 20157:00 amRNSTotal Voting Rights
21st Dec 20157:00 amRNSVernalis Announce CCP-07 Single-Dose Study Results
3rd Dec 20155:19 pmRNSLaunch of 2015 Sharesave Plan
2nd Dec 201511:19 amRNSVernalis Results of Annual General Meeting
2nd Dec 20157:00 amRNSAGM Statement
1st Dec 20154:54 pmRNSHolding(s) in Company
23rd Nov 20155:23 pmRNSHolding(s) in Company
4th Nov 20154:34 pmRNSHolding(s) in Company
30th Oct 20157:00 amRNSTotal Voting Rights
28th Oct 20159:00 amRNSNotice of Annual Report and AGM
15th Oct 20153:54 pmRNSDirector Dealing
15th Oct 20152:02 pmRNSHolding(s) in Company
12th Oct 20157:00 amRNSCCP-08 starts 12 month stability testing
8th Oct 20152:19 pmRNSDirector Dealing
2nd Oct 20157:00 amRNSVernalis plc acquires US rights to MOXATAG®
29th Sep 20157:02 amRNSResults announcement for 18 months ended 30/06/15
25th Sep 201511:09 amRNSBlocklisting Interim Review
16th Sep 20155:08 pmRNSHolding(s) in Company
11th Sep 20157:00 amRNSNotice of Results
8th Sep 20157:00 amRNSVernalis plc Launches Tuzistra(TM) XR
20th Aug 20157:00 amRNSVernalis completes investment in NCE development
18th Aug 20157:00 amRNSAppointment of Non-Executive Director
30th Jun 20151:27 pmRNSAppointment of Non-Executive Director
30th Jun 20157:00 amRNSTotal Voting Rights
12th Jun 20154:34 pmRNSHolding(s) in Company
11th Jun 20157:00 amRNSCCP-07 starts 12 month stability testing
6th May 20151:45 pmRNSBlock Listing Six Monthly Review
6th May 201512:30 pmRNSDirector/PDMR Shareholding
1st May 20154:38 pmRNSHolding(s) in Company
1st May 20157:00 amRNSFDA approves NDA for Tuzistra XR
30th Apr 20153:27 pmRNSHolding(s) in Company
23rd Apr 20152:39 pmRNSHolding(s) in Company
7th Apr 20157:00 amRNSVernalis enters into research collaboration
31st Mar 201512:47 pmRNSTotal Voting Rights
6th Mar 20157:00 amRNSVernalis and AKP Achieve Research Milestone
26th Feb 20157:00 amRNSVernalis licenses proprietary ARA technology
18th Feb 201512:51 pmRNSHolding(s) in Company
10th Feb 20157:00 amRNSUnaudited interim results for periods to 31/12/14
5th Feb 20155:53 pmRNSHolding(s) in Company
30th Jan 201511:50 amRNSNotice of Interim Results Period Ended 31 Dec 2014
26th Jan 20151:06 pmRNSHolding(s) in Company
21st Jan 201511:00 amRNSChange of Non-Executive Director
31st Dec 20147:00 amRNSTotal Voting Rights
19th Dec 20147:00 amRNSUpdate on AUY922 development programme
28th Nov 20147:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.